Evidence map›Paper›PMID 41206792›Full record

Trial reportCirculation2026

Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.

Chao Jiang, Zixu Zhao, Zejun Yang, Yiping Wang, Yang Xu, Hui Xu, Hang Guo, Chi Wang, Liu He, Shijun Xia and 18 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06433479 (Efficacy of DApagliflozin on REcurrence After Catheter Ablation for Atrial Fibrillation), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06433479 nacompletednot on this map

Efficacy of DApagliflozin on REcurrence After Catheter Ablation for Atrial Fibrillation

TypeinterventionalSponsorBeijing Anzhen HospitalRan2024 to 2025Enrolled200ConditionsAtrial FibrillationArmsDapagliflozin 10 mg per day for 3 months after initial catheter ablation
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Chao Jiang *Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0000-0003-1138-7960
Zixu Zhao *Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0000-0002-1311-4299
Zejun Yang *Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0000-0003-3028-6794
Yiping WangDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0009-0002-9604-2573
Yang XuDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).
Hui XuDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).
Hang GuoDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0009-0008-3937-1921
Chi WangCollege of Public Health, University of Iowa, lowa City, IA (C.W.).ORCID 0000-0002-2550-2168
Liu HeDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).
Shijun XiaDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0000-0001-8828-9264
Xiangyi KongDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).
Wenli DaiDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).
Junmeng ZhangDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0000-0003-4670-0670
Song ZuoDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0000-0002-8278-1802
Xiaoxia LiuDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).
Xueyuan GuoDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).
Nian LiuDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0000-0002-3324-8606
Songnan LiDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0000-0002-3139-663X
Ning ZhouDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).
Chenxi JiangDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).
Ribo TangDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0000-0003-2812-1827
Caihua SangDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0000-0002-5421-4421
Paul C ZeiDepartment of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (P.C.Z.).ORCID 0000-0002-3681-2321
Deyong LongDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0000-0003-4604-5346
Xin DuDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0000-0002-7463-8707
Jianzeng DongDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0000-0001-7299-7805
Laurent MacleDepartment of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada (L.M.).ORCID 0000-0002-3328-5239
Changsheng MaDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X.K., W.D., J.Z., S.Z., X.L., X.G., N.L., S.L., N.Z., Chenxi Jiang, R.T., C.S., D.L., X.D., J.D., C.M.).ORCID 0000-0002-5387-5957

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObservational studies have suggested that SGLT2 (sodium-glucose cotransporter 2) inhibitors are associated with a lower risk of atrial fibrillation (AF) recurrence after catheter ablation in patients with AF with concomitant diabetes, heart failure, or chronic kidney disease. However, no randomized trial to date has tested whether SGLT2 inhibitors reduce AF recurrence after ablation in patients without established indications. We therefore investigated the effect of dapagliflozin on prevention of early recurrence of AF after catheter ablation in patients without current indications for SGLT2 inhibitors.

methodsThe DARE-AF trial (Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation) was a prospective, open-label, parallel-assignment randomized controlled trial that enrolled 200 patients with persistent AF between July 2024 and March 2025, scheduled to undergo a first catheter ablation procedure and without established indications for dapagliflozin (diabetes, heart failure, or chronic kidney disease). Patients were randomly assigned at a 1:1 ratio to dapagliflozin (10 mg once daily for 3 months after the ablation) or control. The primary end point was AF burden at 3 months after ablation, assessed by 7-day single-lead ECG patches. Secondary outcomes included time to events, quality of life, and improvement of atrial remodeling.

resultsA total of 200 patients (mean age 58.5 years, 19.5% women, 29.0% with persistent AF ≥1 year) were randomized, and 198 patients (98 in the dapagliflozin group, 100 in the control group) were included in the primary analysis. Three months after ablation, the difference in AF burden was insignificant between the dapagliflozin group and the control group (7.5±23.6% versus 8.1±25.5%;

conclusionsThree-month treatment with dapagliflozin did not reduce the early recurrence of arrhythmia after catheter ablation in patients with persistent AF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06433479.

Indexed as

Atrial FibrillationBenzhydryl CompoundsCatheter AblationGlucosidesSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedProspective StudiesQuality of LifeRecurrenceTreatment OutcomeBenzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorsatrial fibrillationcatheter ablationrecurrenceSGLT2 inhibitor

Identifiers

PMID41206792
PMCPMC12863589

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.